Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-28T18:20:34.400Z Has data issue: false hasContentIssue false
  • English
  • Français

Refractory Status Epilepticus Associated with Anti-SSA (anti-Ro) Antibodies

Published online by Cambridge University Press:  02 December 2014

Jeremy J. Moeller ,
Daniel Friedman ,
Patricia Dugan  and
Cigdem I. Akman
Jeremy J. Moeller*
Affiliation:
Department of Medicine (Neurology), Dalhousie University, Halifax, NS, Canada
Daniel Friedman
Affiliation:
Department of Neurology, NYU Langone Medical Center
Patricia Dugan
Affiliation:
Department of Neurology, NYU Langone Medical Center
Cigdem I. Akman
Affiliation:
Department of Neurology, Columbia University Medical Center, New York, New York, USA
*
Suite 504, 44/46 Portland Street, Dartmouth, Nova Scotia, B2Y 1H4, Canada. Email: jmoeller@dal.ca
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Brief Communications
Information
Canadian Journal of Neurological Sciences , Volume 39 , Issue 5 , September 2012 , pp. 660 - 663
Copyright
Copyright © The Canadian Journal of Neurological 2012

References

1.Dalmau, J.Status epilepticus due to paraneoplastic and nonparaneoplastic encephalitides. Epilepsia. 2009;50(Suppl 12):58–60.CrossRefGoogle ScholarPubMed
2.Liimatainen, S, Peltola, M, Sabater, L, et al.Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia. 2010;51:760–7.CrossRefGoogle ScholarPubMed
3.Peene, I, Meheus, L, Veys, EM, De Keyser, F.Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann Rheum Dis. 2002;61:1090–4.Google Scholar
4.Arbuckle, MR, McClain, MT, Rubertone, MV, et al.Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–33.Google Scholar
5.Delalande, S, de Seze, J, Fauchais, AL, et al.Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83:280–91.Google Scholar
6.Alexander, GE, Provost, TT, Stevens, MB, Alexander, EL.Sjogren syndrome: central nervous system manifestations. Neurology. 1981;31:1391–6.Google Scholar
7.Basir, A, Bougteba, A, Kissani, N.Symptomatic status epilepticus secondary to primary Sjogren’s syndrome. Rev Neurol (Paris) 2010;166:108–10.Google Scholar